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Background: There is good evidence for the positive benefits of pulmonary rehabilitation (PR) 
in the prevention of hospital admissions, lower mortality, and improved health-related quality of 
life. There is also increasing evidence about the impact of PR on mental health and, in particular, 
mood disorders. We aimed to identify how depression in chronic obstructive pulmonary disease 
(COPD) patients in Victoria, Australia, is being managed in PR, to identify the prevalence of 
depressive symptoms among COPD patients who attend PR, and to determine whether patients 
with depressive symptoms or anxiety symptoms dropped out of PR early.
Method: Of 61 PR clinics, 44 were invited and 22 agreed to participate. Telephone interviews 
were conducted to see how depression and anxiety in COPD patients were being recognized 
and managed in these clinics. A total of 294 questionnaires were distributed to patients by clinic 
coordinators to determine the prevalence of anxiety/depression, as measured by the Hospital 
Anxiety and Depression Scale. Coordinators were contacted to provide information on whether 
respondents dropped out of rehabilitation early or continued with their treatment at 2–4 months 
post program.
Results: Seven clinics were not aware of local guidelines on assessment/treatment/management 
of mood. Four clinics did not use any screening tools or other aids in the recognition and 
management of depression and/or anxiety. Overall, eight clinics participating in this study 
requested advice on suitable screening tools. The patient survey indicated that the mean 
depression score on the Hospital Anxiety and Depression Scale was 5.0 (standard deviation 3.0, 
range 1–13). The mean anxiety score was 5.5 (standard deviation 3.4, range 0–18). There was no 
evidence of a link between failure to complete rehabilitation and depression or anxiety scores, 
as only three of 105 patients failed to complete their rehabilitation.
Discussion: Awareness of management guidelines for depression and anxiety in COPD patients 
was variable across the clinics recruited into our study. We found no link between compliance 
with rehabilitation and depression, but our sample had limitations.
Conclusion: Future research needs to investigate how best to encourage more use of available 
guidelines regarding integrating psychological and psychosocial support to supplement the 
exercise and education that are currently offered routinely by all PR clinics studied in Victoria, 
Australia.
Keywords: chronic obstructive pulmonary disease, depression, anxiety, pulmonary 
rehabilitation
Background
The importance of pulmonary rehabilitation (PR) in the management of chronic obstructive 
pulmonary disease (COPD) is now well recognized.1 There is good evidence for the 
positive benefits of PR in the prevention of hospital admissions, lower mortality, and 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
15
O R I g I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.S36378
International Journal of COPD 2013:8
improved health-related quality of life.1 There is also increasing 
evidence for a positive impact of PR on mood disorders such 
as depression and anxiety, which are common comorbidities 
of COPD.2 The published prevalence rates for depression in 
COPD patients vary widely,3–9 but some estimates of depression 
in COPD patients are around 50%10 or, for severe COPD, 
approximately 2.5 times greater than in an age-matched control 
population,11 and significant depression symptoms have been 
reported in 16%–74% of patients with COPD.4,9,12–14 Studies 
employing the Hospital Anxiety and Depression Scale (HADS) 
found estimates of prevalence ranging from 2% to 47%.4–8,15,16 
Undiagnosed and untreated depression in patients with COPD 
is associated with noncompliance with medical treatment and 
reduced quality of life.17 Compared with nondepressed patients, 
the odds are three times greater that depressed patients will 
be noncompliant with medical treatment recommendations.17 
Nevertheless, in Australia, mental disorder comorbidity has 
been grossly under-recognized in patients with COPD.18
Internationally, there are well-established clinical guidelines 
for the treatment of depression and anxiety associated with 
COPD in the United Kingdom.19 According to the British 
guidelines, the presence of anxiety and depression should 
be considered in patients who are hypoxic (SaO
2
 less than 
92%), who have severe dyspnea, and who have been seen at, 
or admitted to, a hospital with an exacerbation of COPD. The 
guidance recommends that patients found to be depressed 
or anxious be treated with conventional pharmacotherapy, 
and, for those undergoing antidepressant treatment, that time 
is spent with the patient explaining why depression needs 
to be treated. Optimal care for COPD patients may require 
combining pharmacologic with nonpharmacologic therapies. 
Pharmacologic treatment of depression in COPD patients 
may be less tolerated than nonpharmacologic treatments, 
due to side effects such as sedation, which may cause 
respiratory depression and aggravate sleep disturbances.20 
Nonpharmacologic therapies include smoking cessation and 
encouragement of physical activity, education, collaborating on 
self-management plans, and cognitive behavior therapy.2,21 In 
Australia we have COPD guidelines that are a joint publication 
from the Australian Lung Foundation and the Thoracic Society 
of Australia and New Zealand.20,22 The Australian guidelines 
summarize international evidence for pharmacologic treatments 
but also summarize the evidence for treatments for anxiety 
and depression. The guidelines include recommendations for 
referrals to psychologists and psychological supports, the use of 
patient support groups for psychosocial supports, and screening 
for anxiety and depression symptoms using standardized 
screening scales such as the HADS.22
Rationale
This project focused on what systems are available for the 
recognition of depression and anxiety at Victorian PR clinics. 
We aimed to identify how depression and anxiety in COPD 
patients are being managed in PR, awareness of management 
guidelines, and the prevalence of depressive symptoms 
among COPD patients who attend PR in Victoria. Although 
the relationship between anxiety, depression, and adherence 
to PR has been examined elsewhere (Harrison et al2), there 
have been no studies of the impact of anxiety and depression 
on adherence to PR as it is practised in Victoria or on the 
relationship between awareness of COPD management 
guidelines and mood disorders in PR patients. Specifically, 
we asked the following research questions:
1.	 How are depression and anxiety in COPD patients 
recognized and managed in PR clinics in Victoria?
2.	 What is the prevalence of depression/anxiety among a 
sample of people attending PR clinics in Victoria?
3.	 Do people who drop out of PR as it is practised in 
Victoria, Australia, have higher anxiety or depression 
scores as measured by the HADS than people who 
complete their course of rehabilitation?
Methodology
We conducted a large, cross-sectional, multicenter study in 
the state of Victoria, Australia, to address the aforementioned 
research questions. To answer research question (1), qualitative 
telephone interviews were conducted with PR coordinators to 
explain programs offered, management of depression/anxiety, 
and awareness of local treatment guidelines of COPD-X19 
and local hospital admission prevention guidelines (Hospital 
Admission Risk Program guidelines). Clinic coordinators were 
invited to participate in the study via email and telephone or 
face-to-face follow-up. Of 61 clinics in the state of Victoria, 
44 were invited and 22 agreed to participate in the study 
(50% response rate). Clinics whose ethics procedures were 
too expensive or outside the time frame of the study were not 
included in the study. The telephone interview covered the 
following topics: reach of the program (number of patients), 
components of the program, use of depression and anxiety 
guidelines, screening tools used, and referral pathways.
To answer research question (2), a total of 294 questionnaires 
were distributed to patients of the 22 PR clinics by clinic 
coordinators. This was a purposive sample (a nonrandom 
sample selected for a specific purpose) of people (both male and 
female aged 18 years of age and above) attending PR following 
a diagnosis of COPD in Victorian PR clinics, within a specified 
time frame, which depended on the length of program cycle run 
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at each clinic. We were not able to select a random sample of 
all patients attending each clinic, because of limitations of time 
and funding. Inclusion criteria were: diagnosis of COPD, over 
18 years of age, and assessed as eligible to attend PR. Because 
we were engaging third-party recruitment, ie, coordinators 
distributed questionnaires on behalf of the research team, 
and because the number of patients attending PR during the 
survey period varied, the number of questionnaires distributed 
to each site varied from six to 25 per clinic. A total of 105 
completed questionnaires were returned, with the response rate 
of questionnaires received from the 22 clinics ranging from 
0% to 90%, and an overall response rate of 36% achieved with 
third-party recruitment of patients.
The self-report questionnaire for patients covered the 
following domains: social well-being (age, sex, marital 
status, living arrangements, social supports), physical 
well-being (COPD history, severity [self-reported, single 
item indicating mild, moderate, or severe], smoking history, 
exercise), psychological well-being (the HADS and Duke 
Social Support Index23 [social interaction component]), and 
service use (PR clinic attendance). The HADS is not a clinical 
diagnostic tool, but it does identify symptoms of anxiety 
and depression and is used to grade severity of symptoms 
using a well-established cutoff point.24,25 Responses on the 
HADS questionnaire are ordinal, ranging from 0 to 3 for 
each item and 0 to 21 for each subscale score. The HADS 
subscale scores for anxiety and depression were calculated 
by summing the scores for each of seven questions, giving a 
total possible score of 21 for each subscale. On the HADS, 
a low score for both subscales of depression and anxiety is 
considered to be less than 7, whereas scores of between 8 
and 10 are suggestive of case-level disorder, and a score 
over 11 indicates significant disorder.25 The scale can be 
administered by a health professional or completed as a 
self-report questionnaire by the patient.24
To answer research question (3), coordinators were 
contacted by the research team to provide information on 
whether respondents dropped out of rehabilitation early or 
continued with their treatment to the satisfaction of their health 
professional at 2–4 months post program. This information was 
then compared with patients’ depression and anxiety scores.
Results
Description of the PR programs
Most programs ran as stand-alone services belonging to 
a larger health organization. All clinics had a multidisciplinary 
team attending to the patients at various stages throughout the 
program. However, the physiotherapist and allied health staff 
were mainly responsible for onsite running of the program. 
Although the overall rehabilitation program resulted from 
multidisciplinary contributions, the physiotherapist usually 
worked alone in providing the exercise component. The 
numbers of patients attending each program varied from five 
to 15 (average n = 8), depending on client compliance and 
attendance since initial assessment to enter the program. Most 
(n = 12) PR programs were run on an ongoing (continuous) 
basis, whereas six clinics ran intermittent programs (one to 
four programs per year). Program sessions varied from once 
weekly for 8–12 weeks to twice weekly for 6–10 weeks.
On average, patients attended twelve program sessions 
based on a twice-weekly, 6-week program cycle.
Components of the programs
All programs (100%, n = 22) included an exercise component 
and an education component, and most, but not all, clinics 
included psychosocial or psychological support to varying 
degrees.
Table 1 shows the amount of psychological and 
psychosocial support offered in the clinics. Over one-
third of clinics (36%) did not offer any psychological 
support to patients. The remainder, 23% (n = 5) offered 
formal psychological support from specialist staff, and the 
majority (63%) offered informal psychological support.
Ten clinics referred their patients to patient support groups, 
and eight clinics had no links to any patient support groups. 
Although there was a general preference by coordinators to 
establish support groups, factors such as varied literacy levels of 
patients, diverse ethnicities, and poor patient compliance acted 
as barriers hindering this type of support being available.
Use of depression and anxiety guidelines/
screening tools/referral pathways
When clinic coordinators were asked about guidelines for 
management of mood in their patients, 32% (seven of 22) 
Table 1 Types of psychological support offered in a sample of 
pulmonary rehabilitation clinics (categories are not mutually 
exclusive)
Type of psychological support Percentage of clinics 
(n = 22)
Formal 23% (n = 5)
Informal
 Psycho-education 14% (n = 3)
 Social worker/counselor 27% (n = 6)
 Support group 9% (n = 2)
 Debrief only 4% (n = 1)
 None 36% (n = 8)
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were not aware of COPD-X guidelines on assessment, 
treatment, or management of mood disorders. The majority 
of coordinators, however, were aware of these guidelines 
and found them to be either useful or very useful in terms 
of applicability to the rehabilitation program. Twenty-three 
percent of coordinators found the guidelines to be very useful 
in forming the framework/structure of the rehabilitation 
program and how the rehabilitation program operates 
broadly. One coordinator, in particular, stated that the 
recent update of these guidelines prompted a revision of the 
clinic’s pulmonary rehabilitation program, and another stated 
that these guidelines were used in annual reviews. A third 
coordinator stated that the Hospital Admission Risk Program 
and COPD-X guidelines ensured uniformity and similarity in 
approach. In addition to these guidelines, one rehabilitation 
clinic also referred to US Pulmonary Best Practice guidelines, 
although none referred to the UK guidelines.
Despite a substantial proportion of clinics not providing 
formal psychological support for their patients, most used 
screening tools or broader psychosocial tools to measure 
quality of life, which to some extent contained emotional 
or psychological indicators of well-being. All except four 
clinics used some specific mood disorder tool, a broader 
tool, or informal methods to screen for depression and 
anxiety amongst their patients. Tools used included the 
Chronic Respiratory Disease Questionnaire, Quality of Life 
Questionnaire, RAND-36 Health-related Quality of Life 
Survey, Short Form-36 Health Survey, GUYATT Quality 
of Life Tool, St George’s Respiratory Questionnaire and 
Depression Anxiety Stress Scales, and the HADS. Overall, 
depression and anxiety screening tools were considered 
useful at all clinics participating in this study, with requests 
for recommendation of suitable screening tools, but many 
clinics did not use tools that were specifically measuring 
depression and anxiety. Some of the issues raised in 
relation to screening tools included that the HADS was not 
particularly useful, due to it being nonspecific to respiratory 
diseases.
When questioned about what paths were used to refer 
patients with depressive symptoms if they were recognized, 
most clinics used either formal or informal referral paths and 
processes to manage patients with depressive symptoms.
These referral paths included referral to community health 
services (eg, counselor, social worker, dietician, client’s 
general practitioner, etc) or to the counselor or psychologist 
within the organization, and providing information regarding 
services such as beyondblue (a community organization 
specialising in anxiety and depression). In instances where 
the client had a mental health care plan, this was taken into 
account in responding to a perceived need to refer, and this 
referral was likely to be to the primary care physician. Often, 
clinics used a care assessment tool that identifies referral 
pathways for risk factors when the client is initially assessed 
to enter a rehabilitation program. In some clinics, all health 
professionals in the multidisciplinary rehabilitation team, 
including the client’s referring doctor, were involved in the 
referral process to a psychologist. Referrals to psychological 
care and support were made through the social worker or 
welfare or other health network structures. Usually, the 
respiratory physician or the counselor was involved in 
referring, with contribution, although to a lesser extent, from 
the client’s primary care physician.
Three clinics followed informal referral mechanisms 
when psychological concerns in patients were identified. This 
was due to inadequate program (organizational) structure and 
lack of means (ie, lack of training to identify and deal with 
patients exhibiting mood disorders, lack of referral processes 
to implement, lack of assessment/screening tools) to manage 
patients with depressive symptoms. Two of these clinics were 
able to identify patients with depressive symptoms through 
this study, which enabled the patients to be referred on for 
further support.
However, again, 32% (n = 7) of clinics did not have a 
process for managing depression. Reasons for not using any 
referral pathways included lack of an onsite psychologist and 
no responsibility for cases where the patient already had a 
doctor managing their mental health.
In summary, although the majority of clinics surveyed 
had some awareness of local guidelines to manage anxiety 
and depression associated with COPD, approximately 
one-third of clinics lacked formal mechanisms for detecting 
mood disorders, adequate staffing to manage symptoms, or 
adequate referral pathways.
Patient sample results
In this context we attempted to determine the prevalence 
of anxiety and depression symptoms in patients from the 
sample of PR clinics. We received questionnaires from 
105 patients, and all questionnaires were completed fully. 
We found that of the sample of 105 patients surveyed in 
these 22 clinics, 43% were male and 57% were female. 
The mean age was 70.9 years (standard deviation [SD] 
8.3 years, range 52–90 years). Approximately one-third 
(31%) lived alone. The mean Duke Social Support Index 
score was 8.0 (SD 1.6). When patients were asked to self-rate 
their COPD symptoms, 20.2% rated them as mild, 67.7% 
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rated them as moderate, and 12.1% rated them as severe. 
Therefore, the majority of these patients were experiencing 
moderate to severe COPD symptoms. Most patients (71.6%) 
were previous smokers. In this sample, the mean depression 
score from the HADS was 5.0 (SD 3.0, range 0–13) and the 
mean anxiety score was 5.5 (SD 3.4, range 0–18). Therefore, 
the mean depression and anxiety scores were within the 
normal range. However, the range of scores indicated that a 
number of patients were experiencing concerning symptoms 
of depression and/or anxiety. When we analyzed scores that 
were suggestive of case-level depression, we found that, 
overall, 20.4% of patients reported depression and 27.2% of 
patients reported suggestive or case-level anxiety. However, 
these patients were not clustered within clinics that had no 
formal psychological supports.
Correlating social network scores with depression and 
anxiety, there was a negative, but nonsignificant, correlation, 
ie, people with lower social network scores tended to have 
higher depression scores, although the relationship was 
not significant. In addition, there was no evidence of a 
link between depression or anxiety symptom scores and 
compliance with programs. We found only three patients 
of the 105 surveyed who did not complete the program of 
PR (one client with high depression/anxiety, two without). 
Therefore, there were insufficient numbers to calculate any 
statistical relationship between completion of PR and the 
HADS subscale scores.
Discussion
Although awareness is growing of the importance of being 
aware of mood disorders and their impact on COPD, we 
found that there is still some way to go in integrating 
psychological and psychosocial support into PR programs in 
Victoria, Australia. Awareness of management guidelines for 
depression and anxiety in COPD patients was variable across 
the clinics recruited into our study. Although some clinics 
were well connected into psychological and psychosocial 
supports for the region, other clinics had very limited access 
to psychological support for their patients and no links to 
patient support groups. Our study showed that although PR 
clinics pay some attention to the psychological well-being 
of patients, there was only moderate use and awareness 
of current guidelines for management of depression and 
anxiety. Results of the client survey indicated that although 
the overall mean depression and anxiety scores were within 
the normal range, there were a fair proportion of patients 
with suggestive or case-level disorder. However, it was 
not related to compliance with the course of rehabilitation. 
Study results of the prevalence of depression in hospital 
samples have been very variable. The prevalence found in 
the present study was in the middle of the range of previous 
prevalence studies.4,9,10,26
The main goals of COPD management are to lessen 
airflow limitation, prevent and decrease symptoms, prevent 
and treat medical complications, and improve daily living 
and quality of life.22 Mood disorders can have a direct effect 
on the likelihood of meeting these goals, and depression 
has been associated with poorer outcomes in patients with 
COPD.14 Unlike previous studies, we found no link between 
compliance with rehabilitation and depression. However, 
our respondents may have been the most motivated ones 
to maintain their program among PR patients. In light of 
limited rehabilitation resources, patients for rehabilitation 
are carefully selected to ensure that they can cope with the 
program, so patients with higher levels of depression or 
anxiety may avoid rehabilitation or be referred elsewhere, 
and patients with higher depression or anxiety who were 
accepted into rehabilitation may have been less likely 
to participate in our survey. The limitations of the study 
were that the 22 clinics that responded to the invitation to 
participate may not have been representative of the other 
clinics in the state. The range of clinics covered large 
government-funded sites as well as smaller community sites 
and rural, regional, and urban settings. The small sample of 
patients surveyed may not have been representative of all 
patients attending PR. Self-rated COPD severity was not 
externally validated with standardized measures such as 
forced expiratory volume in 1 second or forced expiratory 
volume/forced vital capacity. Finally, we were not able 
to determine whether patients with case-level anxiety or 
depression had any previous or current pharmacologic 
or nonpharmacologic treatments, as these data were not 
collected for individuals.
Conclusion
Given the importance of providing psychological and 
psychosocial support for COPD patients in order to maximize 
the effect of rehabilitation on quality of life,23 future 
research needs to investigate alternative models of support 
to supplement the exercise and education that are currently 
offered routinely by all PR clinics studied here. Some studies 
have reported that cognitive behavior therapy can be helpful 
for COPD patients.2 Future research is needed to investigate 
efficient ways to provide psychological and psychosocial 
support as part of PR, as well as at other stages in the pathway 
of management of the disease.
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